Work

Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective

Year: 2021

Type: article

Abstract: The COVID-19 pandemic brought about major changes in cancer clinical trials. In its aftermath, the community has an opportunity to incorporate some of these changes as part of the future of trial conduct to make it more patient centered.

Source: Cancer Discovery

DOI: 10.1158/2159-8290.cd-21-0850

Authors: Keith T. Flaherty, James H. Doroshow, Susan Galbraith, Antoni Ribas, Paul G. Kluetz, Richard Pazdur, Marc R. Theoret

Institutions: Massachusetts General Hospital, National Institutes of Health, National Cancer Institute, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, United States Food and Drug Administration

Language: English

Topic: COVID-19 and healthcare impacts

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, AstraZeneca, Sanofi, Parker Institute for Cancer Immunotherapy, National Institutes of Health, Genentech, Stand Up To Cancer, Chugai Pharmaceutical, National Cancer Institute

Awards: G183821942, G5514976981, G562087445, G8211987807, G9000067102, G9000255545, G9000261587, G9000351677, Cancer Center Support Grant

OpenAlex ID: W3186588062

FWCI: 2.198

Cites: 5

Cited by: 34

Related to: 10